Sederma, a subsidiary of Croda International, holds the trademark for Matrixyl 3000 and supplies it as a branded cosmetic ingredient rather than an active pharmaceutical ingredient The Inkey List. The International Nomenclature of Cosmetic Ingredients assigns the complex two identifiers: Palmitoyl Tripeptide-1 and Palmitoyl Tetrapeptide-7. Matrixyl 3000 is not a research peptide. It is a topical cosmetic ingredient sold through commercial supply chains, not investigational channels.
The statutory boundary governing this complex falls under cosmetic provisions rather than drug statutes. Formulators do not register it through 503B outsourcing facilities. Distributors do not file new drug applications for it. The distinction separates topical cosmetic peptides from the therapeutic peptides that trigger FDA enforcement discretion or pre-litigation notice.
Statutory Classification and INCI Designations
Figure 1: Statutory and nomenclature distinctions between Matrixyl 3000 cosmetic peptides and regulated therapeutic peptides.
The International Nomenclature of Cosmetic Ingredients records the two component peptides as Palmitoyl Tetrapeptide-7 and Palmitoyl Tripeptide-1 NIOD. Retail labeling confirms the same designations The Ordinary. The trade name Matrixyl 3000 identifies the commercial blend of these two palmitoylated peptides, not a single molecule The Inkey List.
A finished product ingredient list from Asterwood records the full formulation: Water, Glycerin, Butylene Glycol, Carbomer, Polysorbate 20, Palmitoyl Tripeptide-1, and Palmitoyl Tetrapeptide-7 Asterwood. The INCI list registers the complex as a single entry. A manufacturer cannot determine the ratio of Palmitoyl Tripeptide-1 to Palmitoyl Tetrapeptide-7 from a finished product label alone.
The supplied records do not contain the text of the Federal Food, Drug, and Cosmetic Act. They document the commercial and nomenclature identity of the complex. Cosmetic peptides differ in regulatory treatment from systemic agents like glp 1 peptides, which require new drug applications and remain subject to active pharmaceutical ingredient controls.
The Statutory Boundary for Topical Peptides
A product intended to affect the structure or any function of the body meets the statutory threshold for a drug. A product intended to cleanse or alter appearance operates under cosmetic provisions. The intended use established by the manufacturer determines the classification.
Matrixyl 3000 appears in topical formulations marketed for the appearance of fine lines. Formulators place it in serums and creams governed by cosmetic labeling standards. Sederma introduced the complex to the cosmetic market in 2003 Klow Peptide. It has remained within the cosmetic regulatory lane since that introduction.
A formulator who markets a peptide complex to treat disease or alter the physiological structure of the body moves the product into drug territory. That reclassification triggers the statutory requirements applied to investigational sequences like ghk peptide when those sequences are formulated for systemic research rather than topical application.
Formulation Concentration Parameters
Commercial suppliers publish specific use concentrations for Matrixyl 3000 in cosmetic manufacturing. Natural Organic Skincare, which lists Sederma as the manufacturer, specifies a 3 to 8 percent concentration for serums, lotions, and eye creams Natural Organic Skincare. The product page identifies the two INCI components as the constituent peptide pair. The 15ml dropper bottle yields approximately 300 drops for formulation dosing Natural Organic Skincare.
Finished consumer products rarely disclose the precise percentage of the complex. The Ordinary sells a formula labeled Matrixyl 10% + HA. The brand does not publish the exact weight percentage of the two palmitoylated peptides within that blend. Asterwood places the complex after water in its ingredient list, indicating its position by weight Asterwood.
These parameters apply to cosmetic manufacturing. They do not constitute pharmaceutical dosing guidelines. Topical signal peptides marketed for appearance claims, such as those grouped under the glow peptide category, operate under the same labeling framework. Readers evaluating the KLOW peptide stack encounter a different multi-compound formulation. Readers assessing how long does it take for peptides to work in topical applications will find timelines governed by collagen remodeling rather than pharmacokinetic review.
Manufacturer studies for Matrixyl 3000 typically report outcomes at eight weeks.
Regulatory Boundary with Therapeutic Peptides
Matrixyl 3000 does not cross into the regulatory categories that govern therapeutic peptides. It does not meet the statutory threshold for an active pharmaceutical ingredient. It does not trigger 503B outsourcing registration. It does not require an administrative stay to maintain market access.
The supplied source records contain no FDA enforcement action, guidance document, or court order addressing Matrixyl 3000. The absence reflects the classification of the complex as a cosmetic ingredient. The FDA regulates therapeutic peptides that target systemic metabolic or disease pathways under drug statutes. The agency regulates topical appearance products under cosmetic statutes.
Manufacturer claims regarding collagen synthesis or wrinkle reduction function as marketing language within the cosmetic framework. The most widely cited study for the complex was conducted by the manufacturer. It reported an approximate 45 percent reduction in deep wrinkle area after two months of application North Biomedical. That figure originates from a Sederma-sponsored trial, not from FDA-reviewed efficacy data.
Clinical studies on the complex were funded or co-funded by the manufacturer, with sample sizes typically between 20 and 40 subjects Klow Peptide.
Those studies support the intended use of the ingredient as a cosmetic. They do not alter its statutory classification. Matrixyl 3000 operates under the Federal Food, Drug, and Cosmetic Act provisions for cosmetics.
